Hyderabad vs Bengaluru vs Visakhapatnam: Choosing a Science Cluster for Pharma, Biotech or Medtech
There is no single best city for life sciences in India; the right one depends on what you make. Hyderabad suits pharma manufacturing, vaccines and large R&D or GCC operations. Bengaluru suits early-stage biotech, research-led startups and companies that need deep scientific and digital talent. Visakhapatnam suits medical device makers that want a dedicated medtech zone with shared testing facilities.
How do the three clusters compare?
Category | Hyderabad (Genome Valley) | Bengaluru (incl. Attibele-Jigani) | Visakhapatnam (AMTZ) |
|---|---|---|---|
Main focus | Pharma, vaccines, bulk drugs, CRO and R&D, GCCs | Biotech, biologics, research-led startups, bioservices, digital health | Medical devices and diagnostics |
Scale signals | 200+ biotech and pharma companies from 18 countries in Genome Valley (CBRE) | Karnataka’s bioeconomy at about $39.2 billion in 2025, 21% of India’s total (Karnataka BioEconomy Report) | 270-acre state-owned medtech park, described as India’s first |
Share of life sciences leasing (2023–25, JLL) | About 35% of national activity; about 45% of life sciences GCC leasing | About 25% of national activity; about 26% of life sciences GCC leasing | Not tracked separately |
Talent depth | Large pool in pharma manufacturing, quality, regulatory and analytics | Strong research institutions and the largest biotech startup base | Smaller pool; engineering and electronics skills relevant to devices |
Shared infrastructure | Purpose-built lab and manufacturing campuses, incubators | Science parks, incubators, research institute partnerships | Shared testing labs, sterilisation and prototyping on site |
Government anchor | Telangana Lifesciences and the state industries department | Karnataka IT, BT department and KITS | AMTZ, owned by the Andhra Pradesh government |
Best fit | Pharma manufacturers, CDMOs, CROs, large R&D centres and GCCs | Early-stage biotech, biologics developers, research spinouts | Device makers from prototype to regulated production |
NQF Hubs’ own cluster data on its Grids page puts the scientific workforce at about 20,000 in Genome Valley, 10,000 in the Attibele-Jigani cluster and 6,000 at AMTZ.
Why choose Hyderabad for pharma and biotech?
Hyderabad has India’s deepest concentration of pharma manufacturing and quality talent, and Genome Valley offers lab and production buildings designed for the job. That matters for companies that need GMP-grade space, effluent treatment and approvals experience close at hand.
The city is also the leading destination for life sciences GCCs. JLL estimates Hyderabad took about 45% of that activity between 2023 and 2025. For a company that wants a GCC and a lab or plant in one city, Hyderabad is the most complete option. See our guide on setting up a life sciences GCC in Hyderabad for the space side of that decision.
Watch for: Genome Valley is some distance from the western IT corridor where much digital talent lives, so hybrid teams need a plan for commuting or split sites.
Why choose Bengaluru for biotech?
Bengaluru’s strength is research depth and startup density. The Karnataka BioEconomy Report 2025 counts 1,451 biotech startups in the state, with 218 added in 2025. The city’s universities and research institutes feed a steady flow of scientists and spinouts, and biologics and bioservices are well established.
The Attibele-Jigani belt on Bengaluru’s southern edge, towards Hosur, is growing as a location for lab and production space beyond the city’s core science parks.
Watch for: compared with Genome Valley, purpose-built GMP manufacturing space is more scattered, so companies moving from research to production should check scale-up options early.
Why choose Visakhapatnam for medical devices?
Visakhapatnam is home to the Andhra Pradesh MedTech Zone (AMTZ), a 270-acre state-owned park at Nadupuru set up in 2016 and widely described as India’s first dedicated medical device park. Its main draw is shared infrastructure that small device makers could not afford alone, including:
Electromagnetic compatibility and electrical safety testing
Biomaterials and sterility testing
A gamma irradiation (sterilisation) centre
3D printing and rapid prototyping
The Andhra Pradesh government has also announced plans for a 500-acre Medical Devices Manufacturing Zone 2.0 in Visakhapatnam, focused on electronic and high-value equipment.
Watch for: the life sciences ecosystem outside devices is smaller than in Hyderabad or Bengaluru. Medtech firms that also need pharma-style talent or biologics expertise may still want a presence in one of the larger cities.
How do you choose the right cluster? A step-by-step check
Define what you will do on site: research, pilot, GMP manufacturing, device assembly, or a GCC.
Match the activity to the cluster’s focus using the table above.
Check talent for your top five roles, not general headcount. Ask recruiters about time-to-hire in each city.
List the shared infrastructure you need: testing labs, sterilisation, effluent treatment, incubators.
Speak to the state agency about approvals and support for your category.
Visit shortlisted campuses and check building specs: floor heights, power, HVAC capacity and expansion space.
Plan for the next stage, not just today. A cluster that suits your pilot should also have room for production.
Can one company use more than one cluster?
Yes, and many do. A common pattern is research or a GCC in Bengaluru or Hyderabad, with manufacturing in whichever cluster best fits the product. Medtech companies often pair a design or software team in a larger city with production at AMTZ.
NQF Hubs (NXT QST FWD) works across all three clusters. Its Solutions page lists operational and under-development campuses in the Hyderabad cluster, BLR District in Bengaluru (20 acres, operational) and Medpolis in Visakhapatnam (20 acres, operational), a medtech campus combining early-stage incubation with production space. For companies planning a move, our guide on relocating R&D and biomanufacturing to Hyderabad or Bengaluru covers the practical steps.
Frequently asked questions
Which Indian city is best for a biotech facility?
It depends on the stage and product. Bengaluru suits research-led and early-stage biotech, while Hyderabad suits companies moving into GMP manufacturing or setting up large R&D and GCC operations. Many companies use both.
Where should a medtech company set up in India?
Visakhapatnam’s AMTZ is purpose-built for medical devices, with shared testing, sterilisation and prototyping facilities. Medtech companies with large software or R&D teams sometimes pair AMTZ production with an office in Hyderabad or Bengaluru.
Is Genome Valley better than Bengaluru for pharma?
For pharma manufacturing, Hyderabad’s Genome Valley usually has the edge, thanks to its concentration of GMP-grade buildings and manufacturing talent. Bengaluru is stronger for biologics research and startups.
What is AMTZ?
AMTZ (Andhra Pradesh MedTech Zone) is a 270-acre medical device manufacturing park in Visakhapatnam, owned by the Andhra Pradesh government. It offers shared facilities such as electrical safety testing, biomaterials testing and gamma sterilisation.
Which city gets the most life sciences investment in India?
By leasing activity, Hyderabad leads. JLL estimates it took about 35% of India’s life sciences leasing over 2023 to 2025, ahead of Bengaluru at about 25%.
Call to action
Weighing clusters for your next facility? Talk to NQF Hubs about available space in Hyderabad, Bengaluru and Visakhapatnam, or arrange campus visits in all three. Get in touch.
3. External sources cited
1. JLL, “India’s life sciences evolves from vaccines to innovation” (13 Apr 2026): https://www.jll.com/en-au/insights/india-life-sciences-evolves-from-vaccines-to-innovation
2. BioSpectrum India, on CBRE “Global Life Sciences Atlas” (15 May 2025): https://biospectrumindia.com/news/109/26121/hyderabad-emerges-as-one-of-the-top-global-centres-of-life-sciences-manufacturing-activity.html
3. BioSpectrum India, “Karnataka’s BioEconomy crosses $39.2 B in 2025, contributing 21% to India’s BioEconomy” (23 Feb 2026): https://biospectrumindia.com/news/16/27376/karnatakas-bioeconomy-crosses-39-2-b-in-2025-contributing-21-to-indias-bioeconomy.html
4. Digital Health News, “Andhra Plans 500-Acre Medical Devices Manufacturing Zone 2.0 in Vizag”: https://www.digitalhealthnews.com/andhra-plans-500-acre-medical-devices-manufacturing-zone-2-0-in-vizag
5. AMTZ background (acreage, founding, facilities): https://en.wikipedia.org/wiki/Andhra_Pradesh_Medtech_Zone
The PDF suggests replacing this with the official AMTZ website if a primary source is preferred.
4. Placeholders to clear
None. The post is ready to publish.
Two notes from the document:
The workforce figures in the line under the table come from NQF’s own Grids page and are attributed to NQF. Its company counts for Attibele-Jigani (100+) and AMTZ (60+) are left out because they could not be matched to a public source.
Hyderabad campuses are not named because some of those names appear in press under another developer. BLR District and Medpolis are named as listed on NQF’s Solutions page.